Overview

A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic CC Failed or Intolerance to Standard Therapy

Status:
RECRUITING
Trial end date:
2027-06-05
Target enrollment:
Participant gender:
Summary
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent/Metastatic Cervical Cancer (CC) Failed or Intolerance to Standard First-Line Therapy.
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Henlius Biotech